Here, we report a case of pneumonia possibly caused by the aspiration of runoff water containing Chromobacterium haemolyticum. A 69-year-old man became intoxicated with alcohol, fell into a ditch, and lost consciousness after suffering a blow to the head. The lower half of his body was completely paralyzed because of damage to his spinal cord, and he aspirated runoff water from the ditch. Chest computed tomography scans revealed consolidation in the right upper lobe and bilateral lower lobes. A sputum culture detected gram-negative bacteria that was identified as C. haemolyticum. Antibacterial chemotherapy was initiated, and the clinical course was favorable. To the best of our knowledge, this is the first report of C. haemolyticum pneumonia in the literature.
SUMMARY:
Here, we report a case of pneumonia possibly caused by the aspiration of runoff water containing Chromobacterium haemolyticum. A 69-year-old man became intoxicated with alcohol, fell into a ditch, and lost consciousness after suffering a blow to the head. The lower half of his body was completely paralyzed because of damage to his spinal cord, and he aspirated runoff water from the ditch. Chest computed tomography scans revealed consolidation in the right upper lobe and bilateral lower lobes. A sputum culture detected gram-negative bacteria that was identified as C. haemolyticum. Antibacterial chemotherapy was initiated, and the clinical course was favorable. To the best of our knowledge, this is the first report of C. haemolyticum pneumonia in the literature.
The genus Chromobacterium consists of 7 recognized species, including C. haemolyticum and C. violaceum. C. violaceum is known to be a native to tropical and subtropical areas with ubiquitous distribution in the soil and water (1) . It is considered a rare and lethal pathogen that causes to sepsis and systemic abscesses (2-4). However, because C. haemolyticum is even more rare, it's natural habitat, and clinical aspects are even less well known (5) (6) (7) (8) .
Herein, we present a case of C. haemolyticum pneumonia that may have been caused by accidental aspiration of runoff water. While antibacterial chemotherapy successfully resolved the pneumonia, C. haemolyticum was detected in the sputum cultures. To our knowledge, this is the first report of C. haemolyticum pneumonia in the literature. In August 2013, a 69-year-old man was admitted to our hospital in cardiopulmonary arrests. He had a previous medical history of cerebral infarction, hypertension, and chronic renal failure. He had become intoxicated with alcohol, fell into a ditch, sustained a blow to the head, and lost consciousness. The lower half of his body was completely paralyzed because of spinal cord damage resulting from the fall, and he aspirated runoff water. A bystander called emergency services, and the patient was taken to our hospital. Upon admission, his Glasgow coma scale score was 3 (Eye opening ＝ 1, Verbal response ＝ 1, Motor response ＝ 1), and he was in cardiopulmonary arrest. His temperature was 33.99 C. An arterial blood gas analysis, obtained with the patient breathing 10 L/min oxygen using a non-rebreather mask, showed a pH ＝ 6.848; PaO 2 ＝ 112 Torr; PaCO 2 ＝ 89.9 Torr; HCO -3 ＝ 14.8 mEq/L; and BE ＝ 23.8 mEq/L. Although the patient's heartbeat recovered after 20 minutes of cardiopulmonary resuscitation, respiration did not. The patient had lost consciousness due to hypoxic encephalopathy, and we initiated mechanical ventilation to counteract hypoxemia. No crackles were heard on auscultation in either lung field. Upon admission, neither a chest radiograph nor a computed tomography scan showed pneumonia. However, based on his medical history, intravenous ampicillin/sulbactam therapy (6 g/day) was started to prevent aspiration pneumonia. On the 2nd day of hospitalization, spontaneous respiration reappeared. The patient had fever and cough with sputum. Coarse crackles were heard in both lung fields. A chest radiograph showed an infiltrative shadow in the right upper lung (Fig. 1A) . Chest computed tomography scans revealed consolidation in the right upper lobe (Fig. 1B) , as well as consolidation with atelectasis in the bilateral lower lobes (Fig. 1C) . Whole body computed tomography scans showed no localized abscesses in the lungs, liver, or spleen. A sputum culture on the 4th day of hospitalization revealed unidentifiable gram-negative bacilli with neutrophil phagocytosis. The bacteria formed white colonies with obvious hemolysis on a sheep blood agar plate (1 × 10 6 CFU/mL; Fig. 1D ) and were identified as C. violaceum using the VITEK 2 system (bioMáerieux, Durham, NC, USA). However, in a recent analysis using stocked bacteria, we identified this bacterium as C. haemolyticum using a 16S rRNA sequence analysis. The MICs for this bacterium were as follows: ampicillin ＞ 64 mg/mL, ampicillin/sulbactam ＞ 64 mg/mL, piperacillin/tazobactam  0.5 mg/mL, cefpodoxime proxetil 16 mg/mL, cefotiam ＞ 64 mg/mL, cefmetazole 8 mg/mL, ceftazidime  0.5 mg/mL, meropenem  0.5 mg/mL, fosfomycin 128 mg/mL, aztreonam 1 mg/mL, gentamicin 4 mg/mL, and levofloxacin  0.25 mg/mL. Sputum cultures revealed no other pathogenic bacteria, including Mycobacterium, and sputum polymerase chain reaction analysis for Mycobacterium tuberculosis and Mycobacterium avium complex were negative. Blood cultures also revealed no bacteria. After intravenous ampicillin/ sulbactam for 7 days, the symptoms remained the same, and the chest radiograph findings were unchanged. A sputum culture on the 7th day of hospitalization revealed Pseudomonas aeruginosa colonization (1 × 10 3 CFU/mL). C. haemolyticum was identified from the sputum culture obtained on the 4th day of hospitalization, therefore, we changed the ampicillin/sulbactam therapy to meropenem therapy (3 g/day) on the 8th day of hospitalization to prevent the pneumonia from worsening. Thereafter, the patient's symptoms began to dissipate, and the abnormal shadow on the chest radiograph gradually improved. On the 10th day of hospitalization, we performed tracheotomy. Although C. haemolyticum was still detected in the sputum culture on the 11th day of hospitalization, the bacterial number was reduced to 1 × 10 5 CFU/mL. Drug eruption due to meropenem appeared by day 8 of therapy, and the antibacterial therapy was changed to intravenous piperacillin/tazobactam therapy (13.5 g/day) and continued for 3 days more. His symptoms and chest radiography findings resolved completely. A sputum culture on the 15th day of hospitalization was negative for C. haemolyticum, and the patient was weaned from mechanical ventilation on that day. The pneumonia did not reoccur, and the patient was transferred to another hospital. C. haemolyticum was also detected in cultures of water from the ditch where the patient had fallen, but a pulsed-field gel electrophoresis analysis showed different patterns between the isolate from the patient's sputum and the isolate from the runoff water. C. haemolyticum and C. violaceum are closely related phylogenetically. C. haemolyticum was one of the first Chromobacterium species to be identified by Han et al. in 2008 (9) , and they reported that C. haemolyticum is distinguishable from C. violaceum in several ways: the lack of violet pigmentation, the ability to hemolyze sheep blood, and differences in several biochemical reactions. In our case, the isolate showed the lack of violet pigmentation and strong hemolytic activity. However, a lack of violet pigmentation alone cannot differentiate C. haemolyticum from C. violaceum. A review of the literature regarding C. violaceum infections found that while most of the clinically-isolated strains of C. violaceum were pigmented; 11z of the isolated strains were non-pigmented (1). In addition, Han et al. pointed out that some cases of C. haemolyticum might be mistaken as non-pigmented C. violaceum by biochemical reactions using the Vitek system's API 20 codes (bioM áerieux) (9) . Furthermore, Okada et al. reported that the Vitek GNI＋ card and the API 20 NE test mistakenly identified isolated C. haemolyticum organisms as C. violaceum (6) . Similarly, in our case, the Vitek II API 20 codes identified the bacterium as C. violaceum, however, the bacterium was later determined to be C. haemolyticum by a 16S rRNA sequence analysis. Therefore, we recommended performing multiple assessments when identifying C. haemolyticum and C. violaceum.
Because of its rarity, little information regarding the clinical aspects of C. haemolyticum infection is known. In two previous cases of C. haemolyticum infection, the bacterium caused necrotizing fasciitis (6) and proctocolitis (7), respectively. However, our case is the first to report that this bacterium caused pneumonia. In the natural environment, C. haemolyticum was isolated from a natural tropical lake in Brazil (5), indicating that similar to C. violaceum (1), C. hemolyticum might inhabit tropical, subtropical, and temperate bodies of water. In the necrotizing fasciitis case in Japan, the route of infection may have been exposure to river water after injury (6) . In our case, we suspected that the route of infection was the runoff water that the patient aspirated. Although, we detected a strain of C. haemolyticum in the water that our patient aspirated, it was a different strain than one identified in the clinically isolated specimen by the pulsed-field gel electrophoresis. C. violaceum infection may rapidly progress to sepsis with multiple organ abscesses, predominantly in the liver, spleen, and lungs (2) (3) (4) , and approximately half of patients with C. violaceum infection die (1). However, the prognosis for the patients with C. haemolyticum infection is not clear. For example, in our case, sepsis was not observed; however, the previous two cases of C. haemolyticum infection developed sepsis, but the patients survived with antibacterial therapy (6, 7) .
There is currently no established antibacterial chemotherapy regimen for C. haemolyticum infection. However, because C. violaceum strains are usually resistant to ampicillin and various cephalosporins (2,10,11). Han et al. has suggested that C. haemolyticum may be more resistant to antibiotics than C. violaceum (9) . For example, the isolate examined in that study was susceptible to ciprofloxacin, imipenem, amikacin, and trimethoprim/sulfamethoxazole, but resistant to cefepime, ceftriaxone, penicillin, penicillin/tazobactam, and ticarcillin/clavulanate (9) . Furthermore, the isolate in the fasciitis case was susceptible to ciprofloxacin and imipenem, but resistant to amikacin (6) while the isolate in the proctocolitis case was susceptible to ceftazidime and ciprofloxacin, but resistant to ceftriaxone and ampicillin (7) ( Table 1) . Van Berkel et al. has suggested that prophylactic use of antibiotics should be restricted to submersion victims who require mechanical ventilation and who have likely aspirated severely contaminated water (12) . We initially administered empirical intravenous ampicillin/sulbactam therapy to treat our patient for predicted aspiration pneumonia, however, the isolate from our patient was resistant to ampicillin/sulbactam. Eventually, our patient went into remission with meropenem therapy followed by piperacillin/tazobactam therapy. Appropriate antibacterial chemotherapy, such as meropenem or ciprofloxacin, would be recommended for C. haemolyticum pneumonia. Relapse sometimes occurs in C. violaceum infection cases (1), and maintenance therapy with an oral agent (such as trimethoprim-sulfamethoxazole, tetracycline, or fluoroquinolone) for 2-3 months is recommended by several authors to help prevent relapse (4, 10, 11, 13) . It is unknown whether we should administer long-term follow up and antibiotic maintenance therapy to prevent for C. haemolyticum infection relapse. In the case of C. haemolyticum that caused fasciitis, physicians administered oral ciprofloxacin followed by intravenous ciprofloxacin therapy as maintenance therapy (6) . In our case, we did not administer maintenance therapy, and the long-term prognosis is unknown because the patient moved to another hospital after the pneumonia improved.
In summary, we have reported a case of C. haemolyticum pneumonia that was successfully treated with antibacterial chemotherapy. Good clinical outcomes may be obtained by administering the appropriate antibacterial chemotherapy. This bacterium should be considered in cases of environmentally associated aspiration pneumonia, and effective antibacterial chemotherapy should be administered accordingly.
